JHVEPhoto Amgen ( NASDAQ: AMGN ) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and Uplizna. Late Tuesday, Amgen ( AMGN ) released data from a Phase 3 study of rocatinlimab in the treatment of atopic.
Back to Health Page
